Učitavanje...

Metabolic reprogramming by N‐acetyl‐seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease

BACKGROUND AND PURPOSE: ACE inhibitors (ACEIs) and AT(1) receptor antagonists (ARBs) are first‐line drugs that are believed to reduce the progression of end‐stage renal disease in diabetic patients. Differences in the effects of ACEIs and ARBs are not well studied and the mechanisms responsible are...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Pharmacol
Glavni autori: Srivastava, Swayam Prakash, Goodwin, Julie E., Kanasaki, Keizo, Koya, Daisuke
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393199/
https://ncbi.nlm.nih.gov/pubmed/32352559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15087
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!